Experimental Bird Flu Vaccine Excels in Animal Models
A vaccine under development at UB has demonstrated complete protection in mice against a deadly variant of the virus that causes bird flu.
Excerpt from the Press Release:
The work, detailed in a study published April 17 in the journal Cell Biomaterials, focuses on the H5N1 variant known as 2.3.4.4b, which has caused widespread outbreaks in wild birds and poultry, in addition to infecting dairy cattle, domesticated cats, sea lions and other mammals.
In the study, scientists describe a process they’ve developed for creating doses with precise amounts of two key proteins — hemagglutinin (H5) and neuraminidase (N1) — that prompt the body’s immune system to fight bird flu.
This process — what’s known as a “vaccine platform” — could help set the experimental vaccine apart from the handful of bird flu vaccines approved for human use in the U.S. and Europe which, while effective, have focused almost entirely on H5 and not N1.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?